

NFkB p65 Antibody FITC Conjugated

Catalog No: #C03882F

Orders: order@signalwayantibody.com

Support: tech@signalwayantibody.com

Description

Product Name	NFkB p65 Antibody FITC Conjugated
Host Species	Rabbit
Clonality	Polyclonal
Isotype	IgG
Purification	Purified by Protein A.
Applications	ICC IF
Species Reactivity	Hu Pig Cow
Immunogen Description	KLH conjugated synthetic peptide aa 130-180 551 derived from human NFkB p65
Conjugates	FITC
Target Name	NFkB p65
Other Names	p65; NFkB3; Transcription factor p65; Nuclear factor NF-kappa-B p65 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; RELA
Accession No.	Swiss-Prot#Q04206NCBI Gene ID5970
Uniprot	Q04206
GeneID	5970;
Excitation Emission	494nm 518nm
Cell Localization	Cytoplasm, Nucleus
Concentration	1mg/ml
Formulation	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Application Details

ICC=1:50-200 IF=1:50-200

Background

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA p65, RELB, NFkB1 p105, NFkB1 p50, REL and NFkB2 p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasion-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B in the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (PubMed:15790681).

Note: This product is for in vitro research use only